Sep-363856
Total Payments
$1.6M
Transactions
450
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.6M | 450 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 450 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia | Sunovion Pharmaceuticals Inc. | $1.6M | 1 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis | Sunovion Pharmaceuticals Inc. | $1,011 | 0 |
Top Doctors Receiving Payments for Sep-363856
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $1.6M | 448 |
| , MD | Neurology | Durham, NC | $3,360 | 2 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.6M
- Total Doctors 1
- Transactions 450
About Sep-363856
Sep-363856 is a drug associated with $1.6M in payments to 1 healthcare providers, recorded across 450 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2018 to 2018. In 2018, $1.6M was paid across 450 transactions to 1 doctors.
The most common payment nature for Sep-363856 is "Unspecified" ($1.6M, 100.0% of total).
Sep-363856 is associated with 2 research studies, including "A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia" ($1.6M).